Smith & Nephew (LON:SN) Stock Price Crosses Above Two Hundred Day Moving Average Following Analyst Downgrade

Smith & Nephew plc (LON:SN)’s share price passed above its two hundred day moving average during trading on Thursday after Citigroup raised their price target on the stock from GBX 1,450 to GBX 1,600. The stock has a two hundred day moving average of GBX 1,151.79 and traded as high as GBX 1,194.50. Citigroup currently has a buy rating on the stock. Smith & Nephew shares last traded at GBX 1,190, with a volume of 6,387,170 shares.

A number of other equities research analysts have also weighed in on the stock. Royal Bank Of Canada boosted their target price on shares of Smith & Nephew from GBX 1,400 to GBX 1,700 and gave the company an “outperform” rating in a research note on Monday, October 20th. JPMorgan Chase & Co. raised their price target on Smith & Nephew from GBX 1,357 to GBX 1,438 and gave the stock an “overweight” rating in a research note on Wednesday, August 6th. Berenberg Bank lifted their price objective on Smith & Nephew from GBX 1,100 to GBX 1,300 and gave the stock a “hold” rating in a report on Thursday, August 7th. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on Smith & Nephew from GBX 1,300 to GBX 1,400 and gave the company a “hold” rating in a research report on Wednesday, August 6th. Three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of GBX 1,242.50.

Smith & Nephew Stock Performance

The company has a debt-to-equity ratio of 73.07, a quick ratio of 0.84 and a current ratio of 2.14. The stock has a market cap of £13.05 billion, a P/E ratio of 42.84, a P/E/G ratio of 0.46 and a beta of 0.69. The business’s 50-day moving average price is GBX 1,056.25 and its 200-day moving average price is GBX 1,151.79.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.